Skip to content
drillr.ai
Sign up

GILD

GILEAD SCIENCES, INC.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$150.11
−0.52%
Ask drillr

  • Sep 16, 2026, 14:30 UTC

    Gilead Sciences committed to advancing a technology-transfer process in Brazil aimed at enabling future local production of lenacapavir.

    Source:

  • Sep 16, 2026, 14:30 UTC

    The Pan American Health Organization (PAHO) announced an agreement with Gilead Sciences to make lenacapavir available for HIV prevention in 14 Latin American and Caribbean countries through its Regional Revolving Funds.

    Source:

  • Sep 16, 2026, 12:32 UTC

    Gilead Sciences extended six royalty-free licensing agreements covering 120 countries.

    Source:

  • Sep 15, 2026, 15:10 UTC

    Gilead Sciences announced an agreement with the Pan American Health Organization to accelerate access to twice-yearly lenacapavir for HIV prevention as PrEP across PAHO Member States in Latin America and the Caribbean.

    Source:

  • Sep 14, 2026, 23:00 UTC

    Gilead Sciences (GILD) shares rose 1.88% to close at $146.42 on the most recent trading day.

    Source:

  • Sep 13, 2026, 01:45 UTC

    Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.

    Source:

  • Sep 8, 2026, 22:50 UTC

    Gilead Sciences' stock price fell 2.88% to $146.64 in the most recent trading session.

    Source:

  • Sep 8, 2026, 20:00 UTC

    Assembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.

    Source:

  • Sep 8, 2026, 17:00 UTC

    Gilead opened a state-of-the-art research center in Foster City, California, to advance the next generation of medicines.

    Source:

  • Aug 28, 2026, 18:02 UTC

    The FDA approved Priovant Therapeutics' Lisraya for dermatomyositis, Gilead Sciences' Bixlenvo for HIV, and an expanded cardiovascular indication for Eli Lilly's Mounjaro.

    Source:

  • Aug 24, 2026, 11:50 UTC

    Qinhao Pharmaceutical licensed global rights of its MAT2A inhibitor GH31 to Gilead Sciences, generating revenue and net profit in the first five months of 2026.

    Source:

  • Aug 22, 2026, 07:12 UTC

    Advisors Capital Management LLC acquired a new position in Gilead Sciences, Inc. by purchasing 31,697 shares worth approximately $4,005,000 during the quarter ended before August 22, 2026.

    Source:

  • Aug 20, 2026, 07:13 UTC

    Abacus FCF Advisors LLC purchased a new stake of 59,974 shares in Gilead Sciences, Inc. during the second quarter, valued at approximately $7,577,000.

    Source:

  • Aug 17, 2026, 08:53 UTC

    AMG National Trust Bank purchased 26,675 shares of Gilead Sciences, Inc., valued at approximately $3,370,000, during the undefined quarter, as disclosed in a recent SEC filing.

    Source:

  • Aug 15, 2026, 08:07 UTC

    Abundance Wealth Counselors increased its stake in Gilead Sciences, Inc. by 93.7% during the quarter, acquiring an additional 10,710 shares, according to its SEC filing.

    Source:

  • Aug 15, 2026, 07:30 UTC

    Benjamin Edwards Inc. reduced its stake in Gilead Sciences, Inc. by 5.0% during the second quarter, selling 6,539 shares and retaining 125,525 shares.

    Source:

  • Aug 14, 2026, 16:27 UTC

    A U.S. Court of Appeals upheld a preliminary injunction against several AFPs and related businesses, barring them from importing Gilead medications from overseas.

    Source:

  • Aug 11, 2026, 20:05 UTC

    Gilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.

    Source:

  • Aug 11, 2026, 11:24 UTC

    Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.

    Source:

  • Aug 7, 2026, 03:07 UTC

    Merck & Co.'s Ebola vaccine and Gilead Sciences' antiviral drug are set for wider use in eastern Democratic Republic of Congo to combat the fastest-growing Ebola outbreak on record.

    Source:

  • Aug 4, 2026, 20:04 UTC

    Gilead Sciences reported second-quarter product sales rose 8%, driven by double-digit gains in HIV drugs, but posted a quarterly loss due to acquisition-related costs.

    Source:

  • Aug 3, 2026, 17:04 UTC

    California's highest court ruled in favor of Gilead Sciences in a 'duty to innovate' case on Monday.

    Source:

  • Jul 30, 2026, 09:49 UTC

    Viread (09887) announced that the Phase II clinical study of Opatsoumab (Viread™, a PD-L1/4-1BB bispecific antibody, LBL-024) for first-line treatment of advanced biliary tract cancer (BTC) has completed enrollment of all 70 patients.

    Source:

  • Jul 14, 2026, 12:48 UTC

    Researchers in the Democratic Republic of Congo began enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the Bundibugyo Ebola outbreak.

    Source:

  • Jul 8, 2026, 00:00 UTC

    Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.

  • Jun 12, 2026, 12:30 UTC

    Gilead Sciences donated more than 2,000 vials of remdesivir to Uganda to support Ebola response efforts.

    Source:
Page 1Next →